A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer

G Mountzios, KN Syrigos - Drug safety, 2011 - Springer
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …
被引用次数：14 相关文章

A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

G Mountzios, KN Syrigos - Drug Safety, 2011 - search.proquest.com
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …
[PDF] academia.edu

[PDF][PDF] A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

G Mountzios, KN Syrigos - Drug Saf, 2011 - academia.edu
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer

G Mountzios, KN Syrigos - Drug safety, 2011 - pubmed.ncbi.nlm.nih.gov
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.

G Mountzios, KN Syrigos - Drug Safety, 2011 - europepmc.org
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

[引用][C] A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

G MOUNTZIOS, KN SYRIGOS - Drug safety, 2011 - pascal-francis.inist.fr
A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …

A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

G Mountzios, KN Syrigos - Drug Safety, 2011 - infona.pl
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer

G Mountzios, KN Syrigos - Drug Safety, 2011 - go.gale.com
Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

[引用][C] A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

G MOUNTZIOS, KN SYRIGOS - Drug safety, 2011 - Adis International